Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL — Stella

View on ClinicalTrials.gov

Recruiting

Back to B-ALL trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Peking University People's Hospital, Beijing

Key details

Phase

Safety & dosing

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.

Enrollment target

~59 participants

Started

January 2025

Primary completion

March 2027

Age range

3 Years – 25 Years

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.